



**Press Release**  
**Virinchi Health Care Private Limited**  
**July 31, 2024**  
**Rating Reaffirmed**

Product	Quantum (Rs. Cr)	Long Term Rating	Short Term Rating
Bank Loan Ratings	68.63	ACUITE BB+   Stable   Reaffirmed	-
Bank Loan Ratings	21.65	-	ACUITE A4+   Reaffirmed
<b>Total Outstanding Quantum (Rs. Cr)</b>	90.28	-	-

**Rating Rationale**

Acuite has reaffirmed its long-term rating of '**ACUITE BB+**' (read as **ACUITE double B plus**) and short-term rating of '**ACUITE A4+**' (read as **ACUITE A four plus**) on Rs.90.28 Cr. bank facilities of Virinchi Health care Private Limited (VHPL). The outlook is '**Stable**'.

**Rationale for rating reaffirmation:**

The reaffirmation of rating takes into account the expected improvement in the operating profit in the coming quarters, based on the past three years trends, despite of decline in operating profit in Q1FY2025 compared to Q1FY2024. The rating continues to draw support from the comfortable financial risk profile, even though the operating income is subdued.

**About the Company**

Incorporated in 2013, VHPL is a 100 percent wholly – owned subsidiary of Virinchi Limited (VL) - a public listed company on the Bombay Stock Exchange and part of Virinchi Group. The company operates a 400 bedded multi-specialty hospital in Banjara Hills, Hyderabad which started operations in August 2016. VHPL is a National Accreditation Board for Hospitals and Healthcare Providers (NABH) and National Accreditation Board for Testing and Calibration Laboratories (NABL) - accredited hospital comprising of 11 operating theatres, 140 ICU beds, 3T MRI, 128 Slice Spectral CT and a ceiling-mounted Cath Lab. VHPL also operates 2 hospitals under the name 'Bristlecone', a 140-bedded hospital at Hayathnagar, Hyderabad and a 60-bedded hospital at Barkatpura, Hyderabad. Virinchi Limited, the holding company, is promoted By Mr. Maddala Veera Srinivasa Rao, Mr. Sri Kalyan Kompella and Mr. Sunder Kanaparthi.

## About the Group

Hyderabad based Virinchi Limited (VL) was incorporated in 1990 by Mr. Vishwanath Kompella, engaged in the business of providing IT based products and services to fintech companies. In the year 2016, Virinchi Health care Private Limited was incorporated with 350 beds capacity at Hyderabad which is 100% subsidiary of Virinchi Limited. The subsidiaries of Virinchi Limited includes Virinchi Healthcare Private Limited, Q fund Technologies Private Limited, KSoft systems Inc, Tensor Fields Consultancy Services Private Limited, Virinchi Combinatorics & Systems Biology Private Limited, Virinchi Learning Private Limited, Virinchi Media & Entertainment Private Limited, Virinchi Infra & Realty Private Limited, Tyohar Foods Private Limited, Asclepius Consulting & Technologies Private Limited.

## Unsupported Rating

Not applicable

## Analytical Approach

### Extent of Consolidation

- Full Consolidation

### Rationale for Consolidation or Parent / Group / Govt. Support

Acuité has consolidated the business and financial risk profile of Virinchi Limited (VL) and its subsidiary - Virinchi Health care Private Limited (VHPL); together referred as Virinchi Group (VG) to arrive at the rating. The consolidation is on account of common management, significant financial linkages and corporate guarantee extended by VL.

## Key Rating Drivers

### Strengths

#### Experienced management and established track record of operations;

Hyderabad based Virinchi Limited (VL) was incorporated in 1990 by Mr. Vishwanath Kompella, engaged in the business of providing IT based products and services to fintech companies. The company's flagship product Q-Fund is used by the alternate finance companies in North America to fund the subprime customers for a short term. In the year 2016, Virinchi Health care Private Limited was incorporated with 350 beds capacity at Hyderabad and current capacity at 600 beds, which is 100% subsidiary of Virinchi Limited. Virinchi Group (VG) is promoted by Mr. Vishwanath Kompella who has more than three decades of experience in IT and Healthcare Industry. The group has an established position in the IT industry of about three decades. VL's revenues are 100 percent export-oriented catering to North America. Acuité believes that VG shall continue to benefit from its long standing presence of more than three decades in the IT and Health care industry and its established position which is likely to result in steady stream of revenues for the company over the medium term.

#### Comfortable financial risk profile:

Financial risk profile of the group is marked by comfortable net worth, capital structure and debt protection metrics. Group's net worth stood at Rs. 360.86 Cr. as on March 31, 2024 as compared to Rs. 244.76 Cr. as on March 31, 2023. Improvement in net worth is on account of ESOPs issued during the year and accretion for profits to reserves. Virinchi group's capital structure is comfortable marked with healthy gearing and total outside liabilities to total net worth (TOL/TNW) of 0.91 times and 1.10 times respectively as on March 31, 2024 as against 1.29 times and 1.55 times as on March 31, 2023. The coverage indicators were moderate with DSCR of 1.50 times as on March 31, 2024 as against 1.64 times as on March 31, 2023. Interest coverage stood at 2.65 times as on March 31, 2024 as against 3.27 times as on March 31, 2023. Debt to EBITDA is continued to remain moderate at 2.90 times as of March 31, 2024 compared to 2.87 times during previous year. Acuite believes that the financial risk profile of the company will remain comfortable for the medium term as well on account of healthy net worth position.

### Weaknesses

#### Continuous decline in operating revenue:

The Virinchi group's revenue has declined during FY2023 to Rs.311.94 Cr. from Rs.364.01 Cr. in FY2022. Decline in revenue is on account of lower revenue reported in healthcare segment. Revenue from healthcare segment have declined by 25 percent in FY23 to Rs.136.16 Cr. The decline in revenue is due to lower IP flow post Covid period followed by moving out of few specialized doctors during last 2 years. The group's revenue further declined to Rs.300.03Cr in FY2024 with a 4 percent decline compared to FY2023. Acuite believes that the operating

revenue of the group will improve in the medium term on account of the expansion plans in healthcare segment.

#### **Intensive working capital operations:**

The working capital operations of the group are intensive which is evident from the Gross Current Assets (GCA) of 254 days in FY2024. Stretch in GCA days is mainly on account of elongated debtor days at 90 days. Receivable period in healthcare segment is generally stretched as the recovery from general insurance, ESI and government's Arogya Shree schemes takes 3-4 months to recover. However, debtors in I.T business will be recovered in 30-45 days. Acuite believes that working capital operations of the group will remain intensive over the medium term as the nature of its operations.

#### **Highly competitive industry and stringent regulatory framework, reputational intensive healthcare sector.**

IT industry is characterized by intense competition from large players enjoying benefits and higher bargaining power. The company also remains susceptible to industry-specific risks, such as exchange-rate fluctuations. However, the entrepreneurial experience is supporting its operating margins. Despite the increasing trend of privatization of healthcare sector in India, the group continues to operate under stringent regulatory control. Accordingly, regulatory challenges continue to pose a significant risk to private healthcare institutions, as they are highly susceptible to changes in regulatory framework. Healthcare is a highly sensitive sector, where any mishandling of a case or negligence on the part of any doctor and/or staff of the unit can lead to distrust among the masses. Thus, all the healthcare providers need to monitor each case diligently and maintain standard of services in order to avoid the occurrence of any unforeseen incident. They also need to maintain high vigilance to avoid any malpractice at any pocket.

#### **Rating Sensitivities**

- Significant improvement in scale of operations while maintaining profitability margins.
- Any large debt-funded capital expenditure, resulting in deterioration of financial risk profile.
- Any further deterioration in working capital management leading to deterioration in financial risk profile and liquidity.

#### **Liquidity position: Adequate**

Virinchi group's liquidity position is adequate which is evident from sufficient net cash accruals (NCA) to meet the debt repayment obligations. The group has reported Net Cash Accruals (NCA's) of Rs.67.01 Cr. for FY2024 against Rs.30.17 Cr. debt repayment obligations. The cash accruals are estimated to remain in the range of Rs.75-80 Cr. in the medium term against expected debt repayment range of Rs.30-25 Cr. for the same period. The current ratio of the group stood at 1.46 times as on March 31, 2024 compared to 1.73 times of March 31, 2023. Acuite believes that liquidity position of the group will remain adequate in the medium term on account of sufficient NCA.

### **Outlook: Stable**

Acuité believes that the group will maintain a 'Stable' outlook over the medium term on account of the extensive experience of the promoters and healthy financial risk profile. The outlook may be revised to 'Positive' if the group achieves substantial improvement in revenue and its working capital management. Conversely, the outlook may be revised to 'Negative' in case of a steep decline in revenues and profitability or financial risk profile leading to deterioration in liquidity.

### **Other Factors affecting Rating**

None

## Key Financials

Particulars	Unit	FY 24 (Actual)	FY 23 (Actual)
Operating Income	Rs. Cr.	300.03	311.94
PAT	Rs. Cr.	13.48	12.72
PAT Margin	(%)	4.49	4.08
Total Debt/Tangible Net Worth	Times	0.91	1.29
PBDIT/Interest	Times	2.65	3.27

### Status of non-cooperation with previous CRA (if applicable)

Not applicable

### Any Other Information

None

### Applicable Criteria

- Application Of Financial Ratios And Adjustments: <https://www.acuite.in/view-rating-criteria-53.htm>
- Consolidation Of Companies: <https://www.acuite.in/view-rating-criteria-60.htm>
- Default Recognition: <https://www.acuite.in/view-rating-criteria-52.htm>
- Rating Process and Timeline: <https://www.acuite.in/view-rating-criteria-67.htm>
- Service Sector: <https://www.acuite.in/view-rating-criteria-50.htm>

### Note on Complexity Levels of the Rated Instrument

In order to inform the investors about complexity of instruments, Acuite has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite's categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria "Complexity Level Of Financial Instruments" on [www.acuite.in](http://www.acuite.in)

## Rating History

Date	Name of Instruments/Facilities	Term	Amount (Rs. Cr)	Rating/Outlook
18 Mar 2024	Term Loan	Long Term	14.47	ACUITE BB+   Stable (Reaffirmed)
	Working Capital Term Loan	Long Term	3.09	ACUITE BB+   Stable (Reaffirmed)
	Cash Credit	Long Term	5.50	ACUITE BB+   Stable (Reaffirmed)
	Term Loan	Long Term	10.92	ACUITE BB+   Stable (Reaffirmed)
	Cash Credit	Long Term	7.50	ACUITE BB+   Stable (Reaffirmed)
	Working Capital Term Loan	Long Term	2.99	ACUITE BB+   Stable (Reaffirmed)
	Term Loan	Long Term	4.90	ACUITE BB+   Stable (Reaffirmed)
	Working Capital Term Loan	Long Term	0.92	ACUITE BB+   Stable (Reaffirmed)
	Term Loan	Long Term	4.05	ACUITE BB+   Stable (Reaffirmed)
	Working Capital Term Loan	Long Term	3.65	ACUITE BB+   Stable (Reaffirmed)
	Proposed Long Term Bank Facility	Long Term	7.15	ACUITE BB+   Stable (Reaffirmed)
	Working Capital Term Loan	Long Term	0.82	ACUITE BB+   Stable (Reaffirmed)
	Working Capital Term Loan	Long Term	2.67	ACUITE BB+   Stable (Reaffirmed)
	Bank Guarantee/Letter of Guarantee	Short Term	2.00	ACUITE A4+ (Reaffirmed)
	Proposed Short Term Bank Facility	Short Term	19.65	ACUITE A4+ (Reaffirmed)
19 Dec 2022	Bank Guarantee/Letter of Guarantee	Short Term	2.00	ACUITE A4+ (Downgraded from ACUITE A3)
	Proposed Short Term Bank Facility	Short Term	5.00	ACUITE A4+ (Downgraded from ACUITE A3)
	Term Loan	Long Term	20.29	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Working Capital Term Loan	Long Term	4.81	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Cash Credit	Long Term	5.50	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Term Loan	Long Term	14.89	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Cash Credit	Long Term	7.50	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Working Capital Term Loan	Long Term	4.51	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Term Loan	Long Term	6.57	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Working Capital Term Loan	Long Term	1.38	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Term Loan	Long Term	5.52	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Working Capital Term	Long		ACUITE BB+   Stable (Downgraded from

	Loan	Term	3.65	ACUITE BBB-   Stable)
	Proposed Long Term Bank Facility	Long Term	7.84	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
	Working Capital Term Loan	Long Term	0.82	ACUITE BB+   Stable (Downgraded from ACUITE BBB-   Stable)
28 Oct 2021	Term Loan	Long Term	6.59	ACUITE BBB-   Stable (Assigned)
	Working Capital Term Loan	Long Term	1.62	ACUITE BBB-   Stable (Assigned)
	Term Loan	Long Term	7.82	ACUITE BBB-   Stable (Assigned)
	Working Capital Term Loan	Long Term	5.30	ACUITE BBB-   Stable (Assigned)
	Cash Credit	Long Term	7.50	ACUITE BBB-   Stable (Assigned)
	Term Loan	Long Term	18.95	ACUITE BBB-   Stable (Assigned)
	Cash Credit	Long Term	5.50	ACUITE BBB-   Stable (Assigned)
	Working Capital Term Loan	Long Term	5.50	ACUITE BBB-   Stable (Assigned)
	Term Loan	Long Term	24.50	ACUITE BBB-   Stable (Assigned)
	Proposed Short Term Bank Facility	Short Term	5.00	ACUITE A3 (Assigned)
	Bank Guarantee/Letter of Guarantee	Short Term	2.00	ACUITE A3 (Assigned)



## Annexure - Details of instruments rated

Lender's Name	ISIN	Facilities	Date Of Issuance	Coupon Rate	Maturity Date	Complexity Level	Quantum (Rs. Cr.)	Rating
Canara Bank	Not avl. / Not appl.	Bank Guarantee/Letter of Guarantee	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	Simple	2.00	ACUITE A4+   Reaffirmed
Canara Bank	Not avl. / Not appl.	Cash Credit	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	Simple	5.50	ACUITE BB+   Stable   Reaffirmed
Central Bank of India	Not avl. / Not appl.	Cash Credit	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	Simple	7.50	ACUITE BB+   Stable   Reaffirmed
Not Applicable	Not avl. / Not appl.	Proposed Long Term Bank Facility	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	Simple	7.15	ACUITE BB+   Stable   Reaffirmed
Not Applicable	Not avl. / Not appl.	Proposed Short Term Bank Facility	Not avl. / Not appl.	Not avl. / Not appl.	Not avl. / Not appl.	Simple	19.65	ACUITE A4+   Reaffirmed
DBS Bank Ltd	Not avl. / Not appl.	Term Loan	16 Sep 2015	Not avl. / Not appl.	30 Sep 2025	Simple	4.05	ACUITE BB+   Stable   Reaffirmed
Punjab National Bank	Not avl. / Not appl.	Term Loan	14 Jul 2015	Not avl. / Not appl.	03 Sep 2025	Simple	4.90	ACUITE BB+   Stable   Reaffirmed
Central Bank of India	Not avl. / Not appl.	Term Loan	03 Jan 2017	Not avl. / Not appl.	30 Sep 2024	Simple	10.92	ACUITE BB+   Stable   Reaffirmed
Canara Bank	Not avl. / Not appl.	Term Loan	28 May 2015	Not avl. / Not appl.	30 Sep 2025	Simple	14.47	ACUITE BB+   Stable   Reaffirmed
Canara Bank	Not avl. / Not appl.	Working Capital Term Loan	Not avl. / Not appl.	Not avl. / Not appl.	31 Mar 2026	Simple	3.09	ACUITE BB+   Stable   Reaffirmed
Punjab National Bank	Not avl. / Not appl.	Working Capital Term Loan	Not avl. / Not appl.	Not avl. / Not appl.	31 Mar 2026	Simple	0.92	ACUITE BB+   Stable   Reaffirmed
Central Bank of India	Not avl. / Not appl.	Working Capital Term Loan	Not avl. / Not appl.	Not avl. / Not appl.	31 Dec 2025	Simple	2.99	ACUITE BB+   Stable   Reaffirmed
Canara Bank	Not avl. / Not appl.	Working Capital Term Loan	Not avl. / Not appl.	Not avl. / Not appl.	31 Dec 2027	Simple	3.65	ACUITE BB+   Stable   Reaffirmed

Punjab National Bank	Not avl. / Not appl.	Working Capital Term Loan	Not avl. / Not appl.	Not avl. / Not appl.	31 Mar 2026	Simple	0.82	ACUITE BB+   Stable   Reaffirmed
Central Bank of India	Not avl. / Not appl.	Working Capital Term Loan	Not avl. / Not appl.	Not avl. / Not appl.	29 Feb 2028	Simple	2.67	ACUITE BB+   Stable   Reaffirmed

**\*Annexure 2 - List of Entities (applicable for Consolidation or Parent / Group / Govt. Support)**

Sr.No.	Company Name
1	Virinchi Limited
2	Virinchi Health care Private Limited

## Contacts

Analytical	Rating Desk
Mohit Jain Senior Vice President-Rating Operations Tel: 022-49294017 <a href="mailto:mohit.jain@acuite.in">mohit.jain@acuite.in</a>  Katta Akhil Analyst-Rating Operations Tel: 022-49294065 <a href="mailto:akhil.katta@acuite.in">akhil.katta@acuite.in</a>	Varsha Bist Associate Vice President-Rating Administration Tel: 022-49294011 <a href="mailto:rating.desk@acuite.in">rating.desk@acuite.in</a>

### About Acuité Ratings & Research

Acuité is a full-service Credit Rating Agency registered with the Securities & Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI) for Bank Loan Ratings under BASEL-II norms in the year 2012. Acuité has assigned ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Kanjurmarg, Mumbai.

**Disclaimer:** An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Ratings assigned by Acuité are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind, arising from the use of its ratings. Ratings assigned by Acuité are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.acuite.in](http://www.acuite.in)) for the latest information on any instrument rated by Acuité. Please visit <https://www.acuite.in/faqs.htm> to refer FAQs on Credit Rating.